Other drugs that have been used in the medical treatment of hypertrophic cardiomyopathy and that are still being studied are Disopyramide, Cibenzoline, Ranolazine and Eleclazine, Sacubitril/Valsartan, Perhexiline, and Trimetazidine [81].  Mavacamten is a novel specific myosin inhibitor that has recently been identified through a chemical screening for molecules decreasing the ATPase rate of myosin in bovine myofibrils, this new molecule seems to be promising in the prognosis of the patients [82]. Here, MYH14 is linked to hypertrophic cardiomyopathy.